Insmed announces strategic financings totaling $775 million

—$500 million secured in non-dilutive structured financings consisting of a term loan and capped royalty financing— —$275 million underwritten offering of common stock— —financings increase cash and cash equivalents and marketable securities to approximately $1.3 billion— bridgewater, n.j. , oct. 19, 2022 /prnewswire/ -- insmed incorporated (nasdaq: insm), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced three strategic financings resulting in aggregate gross proceeds of $775 million.
INSM Ratings Summary
INSM Quant Ranking